奥西默替尼
医学
危险系数
内科学
肺癌
置信区间
临床终点
肿瘤科
随机对照试验
非小细胞肺癌
随机化
无进展生存期
表皮生长因子受体
胃肠病学
总体生存率
外科
癌症
埃罗替尼
A549电池
作者
Byoung Chul Cho,Shun Lu,Enriqueta Felip,Alexander I. Spira,Nicolas Girard,Jong-Seok Lee,Se-Hoon Lee,Yurii Ostapenko,Pongwut Danchaivijitr,Baogang Liu,Adlinda Alip,Ernesto Korbenfeld,Josiane Mourão Dias,Benjamin Besse,Ki-Hyeong Lee,Hailin Xiong,Soon-Hin How,Ying Cheng,Gee‐Chen Chang,Hiroshige Yoshioka
标识
DOI:10.1056/nejmoa2403614
摘要
BACKGROUND: (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC). METHODS: -mutated (exon 19 deletion or L858R), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib (in an open-label fashion), osimertinib (in a blinded fashion), or lazertinib (in a blinded fashion, to assess the contribution of treatment components). The primary end point was progression-free survival in the amivantamab-lazertinib group as compared with the osimertinib group, as assessed by blinded independent central review. RESULTS: -related toxic effects. The incidence of discontinuation of all agents due to treatment-related adverse events was 10% with amivantamab-lazertinib and 3% with osimertinib. CONCLUSIONS: -mutated advanced NSCLC. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, NCT04487080.).
科研通智能强力驱动
Strongly Powered by AbleSci AI